Taysha Gene Therapies (NASDAQ:TSHA) Stock Jumps 6.4% – Should You Buy?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA)’s share price traded up 6.4% on Thursday. The stock traded as high as $3.70 and last traded at $3.7350. 291,380 shares were traded during trading, a decline of 90% from the average daily volume of 3,035,140 shares. The stock had previously closed at $3.51.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. The Goldman Sachs Group increased their price objective on Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Pivotal Research set a $14.00 target price on Taysha Gene Therapies in a research report on Tuesday, June 23rd. Wolfe Research assumed coverage on Taysha Gene Therapies in a report on Thursday, September 17th. They issued an “outperform” rating for the company. Citizens Jmp reiterated a “market outperform” rating and issued a $11.00 target price on shares of Taysha Gene Therapies in a report on Thursday, July 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, September 21st. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $12.77.

Taysha Gene Therapies Trading Up 7.5%

The company has a quick ratio of 17.76, a current ratio of 17.76 and a debt-to-equity ratio of 0.13. The stock’s 50 day moving average price is $5.35 and its 200-day moving average price is $5.68. The stock has a market capitalization of $1.23 billion, a P/E ratio of -8.99 and a beta of 1.19.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). As a group, equities research analysts expect that Taysha Gene Therapies, Inc. will post -0.52 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TSHA. Arizona State Retirement System raised its holdings in Taysha Gene Therapies by 5.4% in the second quarter. Arizona State Retirement System now owns 39,633 shares of the company’s stock worth $270,000 after purchasing an additional 2,014 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of Taysha Gene Therapies by 26.2% during the first quarter. Principal Financial Group Inc. now owns 16,185 shares of the company’s stock valued at $72,000 after buying an additional 3,362 shares during the last quarter. Sei Investments Co. boosted its holdings in shares of Taysha Gene Therapies by 7.6% in the 1st quarter. Sei Investments Co. now owns 51,472 shares of the company’s stock valued at $230,000 after buying an additional 3,614 shares in the last quarter. Chicago Partners Investment Group LLC boosted its holdings in shares of Taysha Gene Therapies by 2.5% in the 1st quarter. Chicago Partners Investment Group LLC now owns 170,751 shares of the company’s stock valued at $763,000 after buying an additional 4,210 shares in the last quarter. Finally, Cetera Investment Advisers grew its position in shares of Taysha Gene Therapies by 34.5% in the 1st quarter. Cetera Investment Advisers now owns 28,450 shares of the company’s stock worth $127,000 after buying an additional 7,296 shares during the last quarter. 77.70% of the stock is owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus-based delivery technologies and other genetic medicine approaches to target conditions with limited or no approved treatment options.

Taysha’s research and development programs have included TSHA-102, an investigational gene therapy being developed for Rett syndrome, as well as programs for other rare neurological disorders.